Compare ASTRAZENECA PHARMA with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CADILA HEALTHCARE - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CADILA HEALTHCARE ASTRAZENECA PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 114.3 29.7 385.5% View Chart
P/BV x 35.0 5.2 673.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ASTRAZENECA PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
CADILA HEALTHCARE
Mar-20
ASTRAZENECA PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,278352 362.8%   
Low Rs883207 427.4%   
Sales per share (Unadj.) Rs228.4139.2 164.1%  
Earnings per share (Unadj.) Rs10.411.8 88.1%  
Cash flow per share (Unadj.) Rs16.318.6 87.6%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs98.8101.4 97.5%  
Shares outstanding (eoy) m25.001,023.74 2.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.0 235.7%   
Avg P/E ratio x104.223.7 438.9%  
P/CF ratio (eoy) x66.415.0 441.5%  
Price / Book Value ratio x10.92.8 396.7%  
Dividend payout %029.8 0.0%   
Avg Mkt Cap Rs m27,008286,033 9.4%   
No. of employees `0001.413.4 10.1%   
Total wages/salary Rs m1,53524,145 6.4%   
Avg. sales/employee Rs Th4,210.910,632.7 39.6%   
Avg. wages/employee Rs Th1,132.21,801.2 62.9%   
Avg. net profit/employee Rs Th191.1898.5 21.3%   
INCOME DATA
Net Sales Rs m5,710142,531 4.0%  
Other income Rs m1231,139 10.8%   
Total revenues Rs m5,833143,670 4.1%   
Gross profit Rs m46324,198 1.9%  
Depreciation Rs m1476,965 2.1%   
Interest Rs m03,418 0.0%   
Profit before tax Rs m43814,954 2.9%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1793,198 5.6%   
Profit after tax Rs m25912,044 2.2%  
Gross profit margin %8.117.0 47.8%  
Effective tax rate %40.821.4 191.0%   
Net profit margin %4.58.5 53.7%  
BALANCE SHEET DATA
Current assets Rs m3,20987,154 3.7%   
Current liabilities Rs m2,07082,694 2.5%   
Net working cap to sales %20.03.1 637.9%  
Current ratio x1.61.1 147.1%  
Inventory Days Days7271 101.3%  
Debtors Days Days3594 37.2%  
Net fixed assets Rs m790133,236 0.6%   
Share capital Rs m501,024 4.9%   
"Free" reserves Rs m2,419102,733 2.4%   
Net worth Rs m2,469103,757 2.4%   
Long term debt Rs m032,146 0.0%   
Total assets Rs m4,605236,866 1.9%  
Interest coverage xNM5.4-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.6 206.0%   
Return on assets %5.66.5 86.2%  
Return on equity %10.511.6 90.4%  
Return on capital %17.713.7 129.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30052,752 0.6%   
Fx outflow Rs m2,01514,504 13.9%   
Net fx Rs m-1,71538,248 -4.5%   
CASH FLOW
From Operations Rs m8825,054 0.4%  
From Investments Rs m-94-10,123 0.9%  
From Financial Activity Rs mNA-10,942 0.0%  
Net Cashflow Rs m-63,989 -0.1%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.3 3.6%  
FIIs % 15.7 5.9 266.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 11.0 82.7%  
Shareholders   12,856 44,069 29.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  TORRENT PHARMA  DISHMAN PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 16, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS